Product Highlight - VERQUVO

The First sGC Stimulator FDA-approved for Reduction of Cardiovascular Death and Heart Failure Hospitalization in Patients with Heart Failure Reduced Ejection Fraction¹
•Studied in patients with symptomatic chronic HF following a worsening HF event^2,3
•Is the only approved treatment specifically restoring the deficient NO-sGC-cGMP pathway⁴
•Reduced the absolute risk of CV death and HF hospitalization by 4.2% vs background therapy alone³
•A viable treatment option for patients with eGFR levels as low as 15 ml/min/1.73 m^{2 3,5}
•Showed no significant difference in symptomatic hypotension compared to placebo, and only 1-2 mmHg reduction in SBP observed in VICTORIA^3,5

CV=cardiovascular; eGFR=estimated glomerular filtration rate; HF=heart failure; NO-sGC-cGMP=nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate; sGC= soluble guanylate cyclase; SBP=systolic blood pressure

References:
1. Tran B-A, et al. Vericiguat: The First Soluble Guanylate Cyclase Stimulator for Reduction of Cardiovascular Death and Heart Failure Hospitalization in Patients With Heart Failure Reduced Ejection Fraction. Journal of Pharmacy Practice. March 2022.
2. Armstrong PW, et al. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial. JACC Heart Fail. 2018;6(2):96-104. doi:10.1016/j.jchf.2017.08.013
3. Armstrong PW, et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2020;382(20):1883-1893.
4. Nelissen E, et al. Neuroscience Letters 2022; 788: 136840.
5. Verquvo 2.5 / 5 / 10 mg film-coated tablets Hong Kong prescribing information (Dec 2021).